MiR-96 Downregulates REV1 and RAD51 to Promote Cellular Sensitivity to Cisplatin and PARP Inhibition

Cancer Research - United States
doi 10.1158/0008-5472.can-12-0103
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

miR-1/206 Downregulates Splicing Factor Srsf9 to Promote C2C12 Differentiation

Skeletal Muscle
OrthopedicsSports MedicineCell BiologyMolecular Biology
2019English

Inhibition of mTOR Downregulates Expression of DNA Repair Proteins and Is Highly Efficient Against BRCA2-mutated Breast Cancer in Combination to PARP Inhibition

Oncotarget
Oncology
2018English

Brca2Deficiency Sensitizes Cells to PARP Inhibition

Cancer Research
Cancer ResearchOncology
2006English

Hypoxic Signaling and the Cellular Redox Tumor Environment Determine Sensitivity to MTH1 Inhibition

Cancer Research
Cancer ResearchOncology
2016English

circRNA_001275 Upregulates Wnt7a Expression by Competitively Sponging miR‑370‑3p to Promote Cisplatin Resistance in Esophageal Cancer

International Journal of Oncology
Cancer ResearchOncology
2020English

Cisplatin Resistance Coupled to Enhanced Sensitivity to Metabolic Interventions

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2018English

ASNA-1 Activity Modulates Sensitivity to Cisplatin

Cancer Research
Cancer ResearchOncology
2010English

PARP Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy

Stem Cells
MedicineMolecular MedicineDevelopmental BiologyCell Biology
2018English

Long Non-Coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving

Cancer Research and Treatment
Cancer ResearchOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy